KR101821468B1 - 벤즈옥사제핀 화합물의 제조 방법 - Google Patents

벤즈옥사제핀 화합물의 제조 방법 Download PDF

Info

Publication number
KR101821468B1
KR101821468B1 KR1020157024484A KR20157024484A KR101821468B1 KR 101821468 B1 KR101821468 B1 KR 101821468B1 KR 1020157024484 A KR1020157024484 A KR 1020157024484A KR 20157024484 A KR20157024484 A KR 20157024484A KR 101821468 B1 KR101821468 B1 KR 101821468B1
Authority
KR
South Korea
Prior art keywords
compound
bromo
acid
formula
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157024484A
Other languages
English (en)
Korean (ko)
Other versions
KR20150119033A (ko
Inventor
레미 엔젤라우드
다니엘 알 뷰드리
다이앤 이 카레라
수샨트 말호트라
트래비스 레마척
프레데릭 세인트-진
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20150119033A publication Critical patent/KR20150119033A/ko
Application granted granted Critical
Publication of KR101821468B1 publication Critical patent/KR101821468B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020157024484A 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법 Expired - Fee Related KR101821468B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779619P 2013-03-13 2013-03-13
US61/779,619 2013-03-13
PCT/EP2014/054786 WO2014140073A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177016062A Division KR101871133B1 (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법

Publications (2)

Publication Number Publication Date
KR20150119033A KR20150119033A (ko) 2015-10-23
KR101821468B1 true KR101821468B1 (ko) 2018-01-23

Family

ID=50241450

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187016976A Withdrawn KR20180070715A (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법
KR1020177016062A Expired - Fee Related KR101871133B1 (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법
KR1020157024484A Expired - Fee Related KR101821468B1 (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020187016976A Withdrawn KR20180070715A (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법
KR1020177016062A Expired - Fee Related KR101871133B1 (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법

Country Status (15)

Country Link
US (1) US9303043B2 (enExample)
EP (3) EP3845540A1 (enExample)
JP (6) JP6363120B2 (enExample)
KR (3) KR20180070715A (enExample)
CN (2) CN108929333A (enExample)
AR (1) AR095365A1 (enExample)
AU (3) AU2014230812B2 (enExample)
BR (1) BR112015020716A2 (enExample)
CA (6) CA2897618A1 (enExample)
IL (1) IL240793A0 (enExample)
MX (1) MX2015011438A (enExample)
NZ (1) NZ711192A (enExample)
RU (2) RU2649976C2 (enExample)
SG (2) SG10201706760YA (enExample)
WO (1) WO2014140073A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180093138A (ko) 2013-12-16 2018-08-20 에프. 호프만-라 로슈 아게 2-(4-(2-(1-이소프로필-3-메틸-1H-1,2,4-트라이아졸-5-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)-1H-피라졸-1-일)-2-메틸프로판아미드의 다형체, 이의 제조 방법 및 이의 약학적 용도
JP6522807B2 (ja) 2015-07-02 2019-05-29 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
CN112047960B (zh) * 2015-07-02 2024-08-02 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
CN105906635A (zh) * 2016-06-08 2016-08-31 上海大学 全氟烷基苯并氮杂*并喹喔啉衍生物及其合成方法
KR20190036549A (ko) 2016-07-29 2019-04-04 니뽄 다바코 산교 가부시키가이샤 피라졸-아미드 화합물의 제조 방법
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
KR102537048B1 (ko) 2016-12-15 2023-05-26 에프. 호프만-라 로슈 아게 (S)-2-((2-((S)-4-(다이플루오로메틸)-2-옥소옥사졸리딘-3-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)아미노) 프로판아미드의 제조 방법
CN108752237A (zh) * 2018-07-05 2018-11-06 四川青木制药有限公司 一种对氨基苯甲脒盐酸盐的新制备方法
KR20210107069A (ko) 2018-12-21 2021-08-31 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 키나아제 저해제의 조합

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110076292A1 (en) * 2009-09-28 2011-03-31 Nicole Blaquiere Benzoxazepin pi3k inhibitor compounds and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
EP1123281B1 (en) * 1998-10-23 2003-10-22 Dow AgroSciences LLC 3-(substituted phenyl)-5-(substituted cyclopropyl)-1,2,4-triazole compounds
JP4463548B2 (ja) 2001-07-12 2010-05-19 リアクサ・リミテッド マイクロカプセル化触媒、及びその製造法と使用法
EP1435951B1 (en) * 2001-10-12 2006-01-18 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the tretment of obesity
WO2007056170A2 (en) 2005-11-02 2007-05-18 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
DK2081937T3 (da) 2006-10-23 2012-10-01 Sgx Pharmaceuticals Inc Triazolopyridazin-proteinkinasemodulatorer
DK2084162T3 (da) * 2006-10-23 2012-10-01 Sgx Pharmaceuticals Inc Bicykliske triazoler som proteinkinasemodulatorer
CA2675755C (en) * 2007-01-19 2015-10-06 Xcovery, Inc. Pyridine and pyridazine derivatives as kinase inhibitors
JP5348725B2 (ja) * 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
WO2009105500A1 (en) * 2008-02-21 2009-08-27 Schering Corporation Compounds that are erk inhibitors
WO2009123971A1 (en) 2008-03-31 2009-10-08 Genentech, Inc. Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
PE20140918A1 (es) 2009-09-28 2014-08-06 Hoffmann La Roche Compuestos de benzoxepina inhibidores de la pi3k
CA2778684A1 (en) * 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
CN102558167A (zh) * 2010-12-29 2012-07-11 中国医学科学院药物研究所 Gk和ppar双重激动活性的噻唑烷二酮衍生物
RU2013143747A (ru) * 2011-03-21 2015-04-27 Ф. Хоффманн-Ля Рош Аг Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения
NO3175985T3 (enExample) * 2011-07-01 2018-04-28
EP2858666B1 (en) * 2012-06-08 2019-09-04 F.Hoffmann-La Roche Ag Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110076292A1 (en) * 2009-09-28 2011-03-31 Nicole Blaquiere Benzoxazepin pi3k inhibitor compounds and methods of use

Also Published As

Publication number Publication date
AU2018201393A1 (en) 2018-03-15
CA2897618A1 (en) 2014-09-18
SG10201706760YA (en) 2017-10-30
AU2014230812A8 (en) 2015-09-10
EP3404032B1 (en) 2025-07-02
AR095365A1 (es) 2015-10-14
JP6663459B2 (ja) 2020-03-11
AU2014230812A1 (en) 2015-09-03
WO2014140073A1 (en) 2014-09-18
SG11201507394RA (en) 2015-10-29
US9303043B2 (en) 2016-04-05
KR101871133B1 (ko) 2018-06-25
CA2948765A1 (en) 2014-09-18
EP2970329A1 (en) 2016-01-20
JP2020114814A (ja) 2020-07-30
CN108929333A (zh) 2018-12-04
CA2948763C (en) 2018-04-24
IL240793A0 (en) 2015-10-29
KR20170070270A (ko) 2017-06-21
AU2014230812B2 (en) 2016-04-07
JP2018150298A (ja) 2018-09-27
HK1215433A1 (zh) 2016-08-26
EP3404032A2 (en) 2018-11-21
AU2016204432A1 (en) 2016-07-21
JP2018008959A (ja) 2018-01-18
KR20150119033A (ko) 2015-10-23
RU2015138488A (ru) 2017-04-20
CN105377856A (zh) 2016-03-02
KR20180070715A (ko) 2018-06-26
JP6442005B2 (ja) 2018-12-19
AU2016204432B2 (en) 2017-12-07
EP3404032A3 (en) 2019-03-13
BR112015020716A2 (pt) 2017-07-18
RU2018109979A (ru) 2019-02-28
CA3005118A1 (en) 2014-09-18
US20140275523A1 (en) 2014-09-18
JP2019089762A (ja) 2019-06-13
JP2016512209A (ja) 2016-04-25
CA3005112A1 (en) 2014-09-18
MX2015011438A (es) 2016-02-03
EP3845540A1 (en) 2021-07-07
CA3005103A1 (en) 2014-09-18
JP6363120B2 (ja) 2018-07-25
JP2019031493A (ja) 2019-02-28
CN105377856B (zh) 2018-05-22
CA2948763A1 (en) 2014-09-18
RU2649976C2 (ru) 2018-04-06
NZ711192A (en) 2019-04-26
EP3404032C0 (en) 2025-07-02

Similar Documents

Publication Publication Date Title
KR101821468B1 (ko) 벤즈옥사제핀 화합물의 제조 방법
US5252584A (en) Hydroxyquinolone derivatives
EA023045B1 (ru) Новые замещенные производные индола в качестве модуляторов гамма-секретазы
KR101698283B1 (ko) 티에노피리미딘 화합물의 제조 방법
SA520412473B1 (ar) مركب أميد حلقي غير متجانس معالج بالنيتروجين واستخدامه لأغراض طبية
EP1042317B1 (en) Indole derivatives as PKC-inhiboitors
WO2000078750A1 (en) New pharmaceutically active compounds
AU2020229920A1 (en) Acryloyl-containing nuclear transport regulator and uses thereof
HK1215433B (zh) 制备苯并氧氮杂䓬化合物的方法
NZ614610B2 (en) Heterocyclic compounds for the inhibition of pask
NZ614610A (en) Heterocyclic compounds for the inhibition of pask

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A107 Divisional application of patent
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210118

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210118

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000